12-Oct-2026 18:00:39
ZYDUSLIFE : PRESENTS NEW POST HOC EPICS-III DATA FOR SAROGLITAZAR IN PBC
• Post hoc analysis of the Phase 3 EPICS-III trial presented at ACG 2026 by Zydus Therapeutics, a wholly owned subsidiary of Zydus Lifesciences • Composite biochemical response rates greater with saroglitazar than placebo in both U.S. (60.7% vs 0%) and non-U.S. subgroups (55.1% vs 13.5%) • Larger treatment difference in the U.S. subgroup (delta 60.7%) versus non-U.S. (delta 41.6%) • ALP normalization treatment difference at Week 52 similar between U.S. and non-U.S. subgroups (7.7% vs 9.6%) • Saroglitazar generally well tolerated; most common adverse reactions were pruritus, headache and urinary tract infection • Saroglitazar is under FDA review; if approved, Zydus Therapeutics plans to launch it in the United States by March 2027
Zydus Lifesciences Limited
Open attachment